Moreover, in PD patients, safety and immunomodulatory effects of sargramostim, a recombinant human GM-CSF that induces Treg via tolerogenic dendritic cells [41], was demonstrated in a phase 1 trial [30, 31]. The gene discussed is CSF2; the disease is Parkinson disease.